This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

GSK wins German nod to acquire CureVac's Covid, influenza vaccines rights

( July 12, 2024, 08:45 GMT | Official Statement) -- MLex Summary: Biopharma business GlaxoSmithKline has received German approval for its plans to acquire intellectual property and patent rights of CureVac with regard to vaccine development, the authority said today. “We must look closely at takeovers in the field of pharma research,” chief Andreas Mundt said, as “it is essential, especially in vaccine development, to protect competition in innovation for patients”. After reviewing the deal under the 2017 transaction value threshold, the authority concluded that a large number of preparations with different mechanisms of action are currently under development in the area of Covid and influenza vaccines.Statement follows. ...

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login